Innovent Biologics (Suzhou) Co. Ltd.
Clinical trials sponsored by Innovent Biologics (Suzhou) Co. Ltd., explained in plain language.
Biopharmaceutical company developing and commercializing monoclonal antibody drugs.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New shot could tame high cholesterol without statins Results expected Sep 2026 (estimated)
- New obesity drug IBI362 shows promise in early trial for chinese patients Results expected Sep 2026 (estimated)
- New drug IBI3033 put to the test in healthy volunteers Results expected Sep 2026 (estimated)
- New drug combo aims to shrink lung tumors before surgery Results expected Nov 2026 (estimated)
- New drug IBI343 shows promise in advanced stomach cancer trial Results expected Dec 2026 (estimated)
-
Can a Two-Drug combo outsmart a common cancer mutation?
Disease control Stopped earlyThis trial is testing whether combining an experimental oral drug called IBI351 with the IV drug cetuximab can shrink tumors in people with metastatic colorectal cancer that has a specific KRAS G12C mutation. The study starts with a small group to find the safest dose, then compa…
Phase 1 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Promising cancer drug trial halted early – only 5 patients enrolled
Disease control Stopped earlyThis early-phase trial tested an experimental drug called IBI3004 in people with advanced solid tumors that could not be removed by surgery. The study aimed to find a safe dose and check for side effects, but it was terminated after enrolling only 5 participants. Because it stopp…
Phase 1/2 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC